Paris, France, and Tarrytown, N.Y. - December 8, 2016 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for DupixentA for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. The investigational biologic therapy Dupixent inhibits signaling of IL-4 and IL-13, two key cytokines required for the type 2 immune response, which is believed to be a major driver in the pathogenesis of the disease.